Vive Summary
• Vive reformulates existing pesticides for the $46 Billion crop
protection industry, addressing issues jeopardizing the industry
• Replace organic solvents with biodegradable or bio-inert polymers
• Working with six global crop protection companies on products with
$8 billion total addressable market
• Six products in field trials with results expected by year end
• Trials demonstrate Vive formulations are more effective than
current products
• Products and process are patented and are 100% owned
• Experienced management team and advisors
• Raised $16 MM to date
2
The Growing Use of Pesticides is Assured
$46B
pesticide industry
Crop Yields are
a Worldwide Issue
•
•
•
•
Population growth
Shrinking arable land
Changing diets
Biofuels
3
Yet Industry Profits are Under Pressure
Patent
Cliff
Lack of
New Molecules
Regulatory
Barriers
Crop Protection Industry
Syngenta | Bayer | BASF | DuPont | Dow
Pressure from Generics
4
Addressing Crop Protection Industry’s Key Issues
Products
Patentable
• New IP without
new active
ingredient
Competitive
•
•
•
•
Economics
Efficacy
Convenience
Grower safety
Approvable
• Avoid toxic
formulations
• Environmental
safety
5
Vive Patented Technology Platform
IP Generating
Innovative
Approvable
• Broadly applicable
reformulation
technology
• Lower
development cost
per product
• Improves
economics,
efficacy, safety,
convenience
• Fast timelines
• Improves
handling and
safety
• Enables water
to act as the only
solvent
6
Vive Technology
Active Ingredient (AI)
Vive Cage
Vive New Product
Not soluble in water
Encapsulates AI
in a water dispersible
(non-toxic) structure
Encapsulated AI
dispersed in water
7
Vive Technology Platform
Water and
bio-inert
polymers
create a
cage that
delivers the
active
ingredient
8
Simple, Scalable Manufacturing
• Low capital cost — uses off
the shelf equipment
• Main inputs are EPA
approved polymers
• Straightforward path to large
commercial scale
• $4 MM capex for 200T
Allosperse plant
Pilot Scale Plant (Five tonnes per year)
9
Low Capex with Significant Product Leverage
Vive 200 Tonne
plant
600 Tonnes of
partner supplied
active ingredient
6,000 Tonnes of
packaged
product with
>$100 MM in
annual revenue
10
Four Levels of IP Protection
Product IP
Patent
Cliff
Application IP
Process IP
Composition of
Matter IP
• 12 issued patents (first expiry 2017)
• 52 patents pending
• 7 families in the US and
internationally
• New products via patentable
reformulations
• First reformulated product patents to
be filed in 2012
Ongoing IP Generation
11
Vive Product Portfolio
Patented Actives
• Developing products with
branded companies
• $5 Billion+ addressable market
• Upfront, milestone and royalty
revenue
Generic Actives
• Developing products to be
distributed through branded
companies
• $3 Billion+ addressable market
• Product revenue
Portfolio Renewal and Extension Model
12
Improved Insecticide Efficacy
• Third party trials tested Vive’s formulated
cypermethrin versus the leading competitive
product, FMC’s Ammo
Treatment
Partnered Product
Pests
Killed
Plant Damage
Vive
90%
1.1%
Ammo
5%
32.5%
(Lower is Better)
• Both products were applied at 0.1ppm
• Tests demonstrated superior performance killing
pests and protecting plants
• Results have been confirmed in 5 different trials
Vive’s formulation was 18x more effective killing pests and
~30x more effective protecting plants from insect damage
What Does it Mean to the Farmer?
Potential product benefits include:
•
Better plant protection – higher yields
•
Buy and use less pesticide – save money
13
Improved Residual Activity
• Trials test how long a product keeps working after
it is applied
• Third party trials tested Vive’s formulated
lambda-cyhalothrin versus the leading premium
product, Syngenta’s Karate Zeon, at identical
concentrations
Treatment
Pests Killed
7 Days Later
Pests Killed
14 Days Later
Vive
90%
76%
Karate Zeon
50%
42%
Partnered Product
• Karate Zeon is marketed against “standard”
products based on its superior residual activity
Vive’s formulation was 80% more effective killing pests both
one and two weeks after application
• Results show that Vive’s formulation is better
after 7 and 14 days
What Does it Mean to the Farmer?
Potential product benefits include:
•
Sustained protection – higher yields, better crops
•
Apply less often – save money and hassle
14
Potential Markets
Crop Protection
TAM => $50 Bn
Beauty and
Industrial
Pharmaceuticals
Nutritionals
Personal Care
TAM => $100 Bn TAM => $300 Bn TAM => $500 Bn
TAM => $425 Bn
Potential Markets > $1 Trillion
15
Corporate
Information
16
Management
Keith Thomas
CEO
Darren Anderson
CTO
Flavio Campagnaro
VP Manufacturing
Skip Campbell
VP Product Creation
Ken Yoon
CFO and VP Corp
Development
Entrepreneur, project management and corporate finance;
Booz Allen, Citigroup, BASc (Toronto), MA (Toronto), MBA (Columbia)
Founding president, 4 issued patents, 24 pending applications, 10 refereed
papers, over 40 conference presentations and publications, PhD (Toronto)
Senior process engineer, scaled large environmental plants; Bennett
Environmental, BASc (UBC), PEng
Boston-based M&A and advisory for high-tech industries, consulting and VC
experience, BA (Williams), MBA (Toronto)
Life sciences venture capitalist, consulting and accounting; VenGrowth, Ernst
& Young, BSc (Western), LLB (Queen’s), MBA (Toronto), CA
Supplemented by 10 advisors with experience at Syngenta, BASF, DuPont, Dow, FMC ,etc.
17
Directors
Neil Reid
Chair
Charlie Fischer
Director
Warren Libby
Director
Bill Lambert
Director
Mark MacDonald
Director
Co-founder, MDS Sciex
Former CEO, Dow AgroSciences; Former Chair, CropLife America and CropLife
International
Former President, Syngenta Canada; Former Chairman, Crop Protection
Institute of Canada
Chairman, Ag Growth International; Former Partner, TD Capital
Former VP, Teachers Private Equity; significant board experience
18
The Vive Opportunity
 $46 Billion global market opportunity with assured demand with
significant potential in additional markets
 Patent cliff, formulation issues and generics are unavoidable
 Disruptive, patented, green technology addresses industry needs
 Products with $8 Billion addressable market in dev and trials
 Strong management team and directors
 Commercial deals in 2013 and product launches in 2014
19